ライフサイエンスコーパス: adverse

1 Adverse cardiac remodeling after myocardial infarction (MI) c

2 At 5 years, the incidence of major adverse cardiovascular and cerebrovascular events was higher

3 peripheral artery disease (PAD) have a higher risk of major adverse cardiovascular events (MACE) compared with those with

4 suggest associations between marijuana and a broad range of adverse cardiovascular risks.

5 s a transcription factor (TF) that mediates protection from adverse effects of hypertonicity by increasing transcription

6 Psychological stress has adverse effects on various human diseases, including those of

7 Sensitivity, specificity, preterm delivery, maternal adverse effects, congenital birth defects, childhood cancer.

8 healthcare burden may account for important health-related adverse effects.

9 l causes at the nodal level and external failures due to an adverse environment, and develop a pair approximation analysi

10 2.09-60.02) or pneumonia (OR 5.37, 95% CI: 1.17-24.65), any adverse event (OR 1.55, 95% CI: 1.03-2.33), adverse events du

11 to adverse events (OR 2.65, 95% CI: 1.04-6.80), any serious adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adverse e

12 ute rejection (BCAR) within 60 weeks after transplantation; adverse event coding was centralised.

13 Combined adverse event data and BCAR episodes from all six CTG trials

14 he ixekizumab Q2W group had at least one treatment-emergent adverse event.

15 Serious adverse events (AEs) occurred in 10% of imipenem/relebactam a

16 t-reported local reactions (LRs) and systemic events (SEs), adverse events (AEs), serious AEs, newly diagnosed chronic me

17 evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5, and its relationship with

18 rawal for any reason (OR 2.61, 95% CI: 1.38-4.96) or due to adverse events (OR 2.65, 95% CI: 1.04-6.80), any serious adve

19 ment (TPVR) is associated with a risk of procedural serious adverse events (SAE) and exposure to ionizing radiation.

20 f-treatment outcomes, culture-conversion rates, and serious adverse events (SAEs) during treatment.

21 lular carcinoma (HCC) because of the potential for profound adverse events and large variations in survival outcome.

22 Adverse events and pharmacokinetic measurements were assessed

23 There was no difference in adverse events between randomised groups.

24 Adverse events consisted primarily of elevated liver tests (6

25 Proportions of patients with adverse events did not differ significantly among groups.

26 .17-24.65), any adverse event (OR 1.55, 95% CI: 1.03-2.33), adverse events due to decreased appetite (OR 3.56, 95% CI: 1.

27 me components, biological and pharmacokinetic measures, and adverse events graded 2 or higher.

28 ts, do not provide information on the time profile of these adverse events or reflect the continuous, lower grade symptom

29 serious adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adverse events related to abnormal liver function tests (OR 1

30 Most adverse events resulted only in symptoms (77%) and 36% were j

31 No serious adverse events were attributed to dihydroartemisinin-piperaqu

32 Adverse events were reported in 58.4% of patients; most (94.4

33 Eight serious adverse events were reported with capsular release and two wi

34 There were no unexpected adverse events with (177)Lu-PSMA retreatment.

35 There were decreased Optimizer-related adverse events with the 2-lead system compared with the 3-lea

36 al toxicity tables that include the incidence of high-grade adverse events, defined by the Common Terminology Criteria fo

37 erse events, defined by the Common Terminology Criteria for Adverse Events, do not provide information on the time profil

38 By a stepwise method to capture all available adverse events, we first extracted data on myelodysplastic sy

39 ys of patient's ICU discharge date to identify and classify adverse events.

40 entify predictors for discontinuation due to inefficacy and adverse events.

41 The prospect of EDCs causing adverse health effects in humans and wildlife has led to the

42 of social participation in the community also mitigated the adverse impact of housing damage on functional status, sugges

43 rsely proportional to age, such that frailty had a stronger adverse impact on younger patients.

44 Here we show that Dysf(-/-) mice develop adverse LV remodeling following I/R injury secondary to the c

45 Thus, our data point to potential adverse neurobehavioral consequences of exposure to saccharin

46 Persistent smoking may cause adverse outcomes among patients with cancer.

47 Obesity may contribute to adverse outcomes in coronavirus disease 2019 (COVID-19).

48 Adverse prognostic features of the cohort included short medi

49 engineered versions of the mAb could be used to reduce such adverse reactions.

50 of 0.63, 0.43, and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001).